Meithromax

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Meithromax

What is Meithromax?

Meithromax is an antibacterial medication belonging to the macrolide class of antibiotics. It is formulated to address a variety of bacterial infections by interfering with the way specific bacteria produce the proteins necessary for their survival and growth.

Mechanism of Action

The active component in Meithromax works by binding to the 50S subunit of the bacterial ribosome. By doing so, it inhibits RNA-dependent protein synthesis. This action is typically bacteriostatic, meaning it prevents the bacteria from multiplying, although it can be bactericidal against certain organisms at high concentrations. This process allows the body's immune system to effectively identify and eliminate the remaining pathogens.

Therapeutic Use

Meithromax is utilized in clinical settings to manage infections caused by susceptible microorganisms. It is commonly associated with the treatment of several types of conditions, including:

  • Respiratory Tract Infections: This includes infections of both the upper and lower respiratory system, such as bronchitis and certain types of pneumonia.
  • Skin and Soft Tissue Infections: It is used for uncomplicated infections of the skin layers and underlying tissues.
  • Ear and Throat Infections: This includes conditions such as acute otitis media, pharyngitis, and tonsillitis.
  • Genitourinary Infections: The medication is also used to treat specific sexually transmitted infections involving the urethra or cervix.

Because Meithromax specifically targets bacterial structures, it is not effective against viral infections, such as the common cold or influenza. Its chemical structure is designed to provide stability against gastric acids and allow for a high level of tissue penetration, resulting in prolonged activity within the body.

Regulatory References

  1. Azithromycin Pharmacokinetics (NIH)
  2. U.S. National Library of Medicine
  3. Azithromycin – StatPearls (NIH, 2024)

What side effects are possible with Meithromax?

Possible Side Effects and Safety Information

The safety profile for Meithromax, containing azithromycin, is characterized by its officially documented adverse reactions, classified by frequency and affected organ system, as published in government regulatory labels.

Frequency-Classified Adverse Reactions

The most Common adverse reactions, affecting up to 1 in 10 patients, typically involve the Gastrointestinal System, including diarrhea, loose stools, nausea, abdominal pain, and vomiting, along with headache. Less frequent, or Uncommon, reactions may involve dizziness, somnolence, and certain skin rashes, according to official labeling.


Serious Adverse Reactions and Safety Constraints

Regulatory documentation highlights the existence of Rare but clinically significant adverse reactions. These include a risk of serious cardiac events like QT interval prolongation and Torsades de pointes, as well as severe hepatic issues such as fulminant hepatitis. Other documented serious events include severe cutaneous reactions, such as Stevens-Johnson syndrome (SJS), and Clostridioides difficile-Associated Diarrhea (CDAD), which may occur even after treatment is concluded.


Population-Specific Considerations

The official safety information notes specific cautions for certain patient groups. Older adults may have an increased susceptibility to drug-induced cardiac arrhythmias. Use is contraindicated in individuals with a history of cholestatic jaundice/hepatic dysfunction associated with prior azithromycin use, and caution is required in patients with severe renal impairment or pre-existing proarrhythmic conditions. The label also notes that use in neonates (up to 42 days of life) is associated with a risk of Infantile Hypertrophic Pyloric Stenosis (IHPS).

Overdose and Emergency Response

Overdose and when to seek help

The information in this section is derived exclusively from authoritative government regulatory documents regarding overdose with azithromycin, the active ingredient in Meithromax.

Overdose with Meithromax is documented in regulatory labeling as an exaggeration of known adverse events seen at normal doses. The core manifestations include severe gastrointestinal symptoms and a risk of serious cardiotoxicity.

Documented Manifestations and Severe Outcomes

Official prescribing information lists severe nausea, vomiting, diarrhoea, and reversible loss of hearing as typical presentations of overdose. The most critical, life-threatening outcome noted in regulatory warnings is the potential for QT interval prolongation leading to cardiac arrhythmias and the serious, potentially fatal irregular heartbeat known as Torsades de pointes.

When to Seek Urgent Help and Required Actions

Immediate medical attention must be sought for any suspected overdose. If the affected individual collapses, has a seizure, or experiences trouble breathing, contact emergency services immediately. For less acute situations, contact the poison control helpline.

No specific antidote is known for azithromycin overdose. Regulatory documents mandate that management is symptomatic and supportive, including measures to sustain vital functions and the possible administration of medicinal charcoal to manage absorption. Hospital monitoring is often required due to the potential for severe cardiac events.

Therapeutic Uses of Meithromax

What Meithromax Treats: Main Uses and Benefits

Meithromax is commonly applied in clinical settings that involve acute or unstable symptom patterns arising from bacterial infections of the respiratory system, including pneumonia, acute exacerbations of chronic bronchitis, and infections of the sinuses and throat. It is relevant when short-term symptomatic assistance is needed, helping address symptom clusters that may become intense or disruptive, such as persistent cough, chest congestion, and high fever caused by susceptible bacteria. This provides support that helps ease the overall symptom burden and supports the patient during difficult episodes by easing distress during symptomatic phases.

It is relevant in contexts marked by increased discomfort or tension arising from specific infections of the skin and soft tissues and the genitourinary tract, including Chlamydia. It is also applied as an essential alternative treatment for conditions like bacterial pharyngitis in patients with penicillin allergies, or for long-term prevention (prophylaxis) of recurrent, debilitating episodes in certain chronic conditions. This supportive role **offers symptomatic relief that helps patients cope more steadily.


Quick Fact: Symptomatic Support for Acute Manifestations

Domain Conditions Treated (Examples) Symptom Management Focus
Respiratory & Ear Pneumonia, Acute Bronchitis, Otitis Media, Sinusitis Fever, Congestion, Localized Pain
Targeted Infections Chlamydia, Skin/Soft Tissue Infections Inflammation, Purulent Discharge

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility requirements for Meithromax (azithromycin) based strictly on governmental regulatory documents.

Populations That Must Not Use Meithromax (Contraindications)

Use of this medicine is formally contraindicated in patients with the following conditions:

  • Hypersensitivity: A known allergic reaction (hypersensitivity) to azithromycin, erythromycin, or any macrolide or ketolide antibiotic.
  • Hepatic History: A past history of cholestatic jaundice or hepatic dysfunction specifically associated with prior use of azithromax.

Eligibility Restrictions and Special Caution

Use is allowed for adults and certain pediatric patients, but it requires special consideration or is restricted in the following groups:

Population Group Eligibility Status (Regulatory Basis)
Cardiovascular Risk Use with caution in patients with known QT interval prolongation, proarrhythmic conditions (e.g., uncorrected low potassium or magnesium, clinically slow heart rate), or those receiving certain antiarrhythmic agents.
Pediatric Patients Safety and effectiveness for many uses are not established for children under six months of age. Use in neonates (up to 42 days old) carries a warning due to the reported risk of Infantile Hypertrophic Pyloric Stenosis (IHPS).
Severe Illness Not recommended for patients with pneumonia who are inappropriate for oral therapy due to moderate-to-severe illness or risk factors, such as suspected bacteremia or need for hospitalization.
Renal Function Use with caution in patients with severe renal impairment (Glomerular Filtration Rate <10 mL/min).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Meithromax (azithromycin) is officially characterized by specific pharmacokinetic and pharmacodynamic interactions as documented in regulatory sources.


Documented Interaction Patterns

Classification Interacting Substances/Effect Official Constraint/Description
Pharmacodynamic QT-Prolonging Medicines (e.g., antiarrhythmics like Amiodarone, Sotalol) Increased risk of QT interval prolongation and potential ventricular arrhythmias due to an additive effect.
Pharmacokinetic (Transporter) P-glycoprotein (P-gp) Substrates (e.g., Digoxin, Colchicine) Azithromycin is an official P-gp inhibitor, which may result in increased serum levels of the co-administered drug.
Pharmacokinetic (Absorption) Aluminum- and Magnesium-Containing Antacids Co-administration reduces the peak plasma concentration (Cmax) of azithromycin, necessitating a mandated separation of doses.
Exposure Modification Nelfinavir Results in a documented significant increase in the systemic exposure (Cmax and AUC) of azithromycin.

Contraindication and Timing Rules

Official prescribing information strongly advises against co-administration with substances such as cisapride due to the high risk of serious cardiac events. To mitigate the absorption interference from antacids, oral azithromycin must be administered at least 1 hour before or 2 hours after the antacid. Unlike some macrolides, regulatory labels specify that azithromycin is not a significant inhibitor or inducer of major Cytochrome P450 enzymes.

Mechanism of Action

Meithromax (Azithromycin) exerts its influence through two principal mechanistic domains: a primary antibacterial action and a secondary immunomodulatory effect on the host.

Blocking Bacterial Growth Machinery

This core mechanism involves the drug's targeted interaction with the bacterial 50S ribosomal subunit. By binding to the 23S rRNA within the ribosome's exit tunnel, Meithromax physically inhibits the elongation of essential proteins, thereby halting microbial proliferation and achieving a bacteriostatic effect , which influences the microbial clearance process.

Modulating Host Inflammatory Responses

Separate from its antimicrobial function, the molecule acts as a modulator of the body's immune pathways, particularly in tissues where it accumulates within phagocytic cells. This action modulates inflammatory processes by suppressing the release of pro-inflammatory mediators, such as Interleukin-8 (IL-8) , resulting in reduced neutrophil chemotaxis and mediator release, influencing tissue inflammatory signaling.

Understanding Mechanistic Constraints

The drug's mechanism is physiologically constrained by resistance pathways in some bacteria, primarily through the genetic acquisition of the erm gene, which chemically modifies the ribosomal target site, or the mef gene, which encodes an active efflux pump. These limitations bypass the inhibitory mechanism, resulting in the resumption of bacterial protein synthesis and proliferation.

Dosage and Administration Information

Meithromax (azithromycin) is officially administered via the oral route as tablets or suspension, and the intravenous (IV) route as a diluted infusion for initial hospital treatment. Standard adult oral dosing typically follows one of two patterns: a 500 mg starting dose on Day 1 followed by 250 mg once daily on Days 2 through 5, or 500 mg once daily for 3 days. A total course of therapy may also involve sequential use, such as two days of 500 mg IV infusion, followed by oral dosing to complete a 7 - to 10 -day regimen. For certain single-dose protocols, 1000 mg is the labeled oral dose.

The timing of oral administration is dependent on the specific formulation: standard tablets and suspensions may be taken with or without food, while the extended-release suspension and certain capsules must be taken on an empty stomach (at least 1 hour before or 2 hours after a meal). A key contextual constraint is the requirement to separate the dose from antacids containing aluminum or magnesium by at least one hour before or two hours after administration. For IV administration, the lyophilized powder requires reconstitution and further dilution before being administered as a controlled infusion over a minimum of 60 minutes.

For specific populations, no dose adjustment is required for older adults or individuals with mild-to-moderate renal or hepatic impairment. Pediatric dosing is determined by body weight (mg/kg). If a single daily dose is missed, it should be taken immediately if less than 12 hours have passed; otherwise, it must be skipped, and the standard schedule resumed, strictly avoiding a double dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Meithromax

Evidence for use in Chronic Insomnia

Meithromax was studied for conditions characterized by fluctuating or episodic manifestations of difficulty sleeping. The research primarily consisted of short-term controlled trials, many lasting only a few weeks, which used in research exploring how symptoms change over time. These trials typically included adults diagnosed with chronic insomnia and focused on outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort related to sleep. Researchers monitored measurements like the time it took subjects to fall asleep and the total duration of sleep, often using both subjective patient reports and objective lab measurements.

The findings describe patterns observed in the studies where participants described patterns related to their sleep over the short trial duration. However, studies report how symptoms evolved in the observed populations, and often the patient-reported changes were more frequently described than the objective measurements taken in the sleep lab. The data show patterns related to changes measured during the brief study window.

Evidence for use in Anxiety Disorders

Meithromax was evaluated in research exploring short-term symptom changes in people diagnosed with Anxiety Disorders, specifically Generalized Anxiety Disorder (GAD). The studies used in research exploring how symptoms change over time were typically randomized controlled trials that applied in studies examining patient-reported experiences of anxiety using standardized rating scales. These scales measured outcomes related to systemic or functional imbalance and severity over time intervals ranging from a couple of months up to approximately six months.

The research highlights changes measured during the study period on these standardized rating scales compared to placebo groups. Findings were mixed across some studies regarding the extent and uniformity of the reported score changes. The evidence derived from settings with varying symptom burdens indicates that measured changes in severity was observed in some studies. These studies contribute to the broader evidence landscape by showing patterns related to how symptom scores evolved within the observed populations.

What is Still Uncertain about Meithromax Research

Long-term effects are not fully established across all indications. The follow-up durations were limited, meaning there is a consistent gap in understanding the durability of the reported changes and what happens after many months or years of use. This lack of extended-duration data means that certainty remains low regarding potential long-term benefits or safety concerns that may emerge over a prolonged period.

Research was evaluated in adults for most indications. Data for certain groups remain insufficient, particularly concerning children and adolescents. Comparative evidence is lacking to fully understand how Meithromax compares to other available options, as many studies primarily compare it to an inactive substance (placebo). Findings were mixed across some research areas, leading to variability in the observed patterns.

Key Studies & References

  1. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults (AASM)
  2. Systematic Review of Antidepressants for Anxiety Disorders
  3. Observational and Post-marketing Analysis of Long-term Safety and Cardiovascular Risk

Frequently Asked Questions (FAQ)

Common questions about Meithromax (FAQ)


Q: Can Meithromax be used by people with a history of heart issues?

Official documents advise that caution should be used when Meithromax is prescribed for individuals with certain pre-existing heart conditions. Specifically, regulatory information highlights the potential risk of serious cardiac events in patients with a known history of QT interval prolongation or other proarrhythmic conditions, such as uncorrected electrolyte imbalances. These cautions are due to the documented potential for effects on heart rhythm.


Q: Does Meithromax require any special monitoring by a doctor?

While there is no universal requirement for all patients, official information indicates that monitoring may be considered for certain conditions. For example, patients with known cardiovascular risk factors, such as specific electrolyte disturbances (low potassium or magnesium), may benefit from monitoring before and during the use of Meithromax to reduce the potential for cardiac side effects.


Q: Is the research evidence for Meithromax strong or limited?

Meithromax (azithromycin) is a highly recognized medicine and is included on the World Health Organization's Model List of Essential Medicines. Evidence supporting its use in designated bacterial infections is documented in regulatory sources. However, official research summaries often note limitations regarding the long-term follow-up duration for some indications that have been examined.


Q: Can Meithromax be used during pregnancy or breastfeeding?

For use during pregnancy, regulatory data indicates use should be considered only when the potential benefit is judged to outweigh the potential risk. Regarding breastfeeding, official product information advises caution because the active ingredient, azithromycin, is excreted in human milk. A healthcare provider must carefully consider its use in these populations.


Q: What are the long-term effects of taking Meithromax?

For most approved uses, Meithromax is administered as a short-term treatment over a course of several days. The long-term effects are not fully established across all indications. Official research documents often note limited follow-up durations, meaning data on effects over many months or years is limited.


Q: Is there a different form of Meithromax (e.g., liquid instead of pill)?

Yes, Meithromax is manufactured in several core dosage forms to accommodate various patient needs and routes of administration. These forms include a standard film-coated tablet, a powder for oral suspension (which is a liquid form), and a sterile lyophilized powder used for reconstitution into an intravenous (IV) solution.


Q: Is Meithromax the same kind of drug as [common similar drug type]?

Meithromax contains the active ingredient azithromycin, which is officially classified as an azalide and is a member of the larger family of macrolide antibiotics. This classification defines the drug’s structure and its primary mechanism of action in controlling bacterial growth.


Q: Does Meithromax start working immediately?

The drug begins its primary action of inhibiting bacterial protein synthesis after the first dose. However, because Meithromax is designed to accumulate in body tissues, the time it takes for clinical symptoms to noticeably improve can vary based on the type and location of the infection being treated.


Q: How long does Meithromax stay in your system after stopping the medicine?

Meithromax has a prolonged half-life, which is why it can be taken for a shorter duration compared to some other antibiotics. Due to its unique ability to rapidly distribute into body tissues, measurable amounts of the drug may remain in the tissues for a prolonged period after the full course of therapy is completed.


Q: Is it normal to feel tired when taking Meithromax?

Official regulatory documents, which list possible side effects, indicate that fatigue (tiredness) has been reported as an adverse reaction in some users. While it is not typically one of the most common side effects listed, its occurrence is documented in official safety information.


Q: Can you take Meithromax if you have a history of [specific organ issue, e.g., kidney problem]?

Official prescribing information states that use is allowed, and no dose adjustment is typically necessary for individuals with mild-to-moderate renal or hepatic impairment. However, caution is advised in patients with severe renal impairment or those with a history of hepatic dysfunction specifically associated with prior azithromycin use.


Q: What are the most common reasons people stop taking Meithromax?

Data from clinical trials indicate that most adverse reactions reported were mild to moderate in severity. The most frequent reasons patients discontinued the therapy were generally related to gastrointestinal side effects, such as nausea, vomiting, or diarrhea.


Q: Is Meithromax a maintenance drug or a short-term treatment?

Meithromax is primarily designed and administered as a short-term treatment for acute bacterial infections, with courses of therapy typically ranging from 3 to 10 days. Long-term or maintenance use is not common, except for a few specific prophylactic indications found in official documents.


Q: Are there any foods or drinks that interact with Meithromax?

Regulatory labels do not describe specific interactions with common foods or drinks. The main food-related restriction is that certain oral formulations, like the extended-release suspension, must be taken on an empty stomach to ensure proper absorption into the body. Antacids containing aluminum or magnesium also require a mandatory separation from the dose.


Q: Can Meithromax affect the results of blood tests?

Yes, regulatory documents list some documented effects on blood-related measures as possible, though rare, adverse reactions. These effects may include changes in white blood cell counts and temporary changes in measures of liver function tests (elevated liver enzymes). These changes are factors that may be monitored by a healthcare provider.


Q: Is there a generic version of Meithromax available?

Yes, Meithromax contains the active ingredient azithromycin, which is widely available from various manufacturers as a generic prescription medicine.


Q: Why does the packaging say to be careful with sun exposure while using Meithromax?

Official adverse reaction reports include photosensitivity (increased sensitivity to the sun) as a documented skin reaction, though it is not one of the most common effects. Due to this potential, patients are sometimes informed of the potential need to limit exposure to direct or artificial sunlight.


Q: Can elderly patients use Meithromax safely?

The dosage for elderly patients is similar to that of younger adults, and regulatory documents state that no dose adjustment is typically required based on age alone. However, older adults may have an increased susceptibility to certain drug-associated effects, particularly those involving the QT interval (heart rhythm).


Q: Is Meithromax considered a 'strong' medicine?

Meithromax is formally classified as a broad-spectrum macrolide antibiotic and is recognized for its ability to treat designated susceptible bacterial infections. Its inclusion on the World Health Organization's Model List of Essential Medicines indicates its clinical significance and effectiveness against these pathogens.


Q: How quickly do the benefits of Meithromax become noticeable?

The drug is designed to work over a short course of treatment to control the growth of bacteria. The clinical improvement is dependent on the type and severity of the infection, but clinical improvement is typically observed shortly after beginning the short course of therapy.


Q: Is it possible to develop a resistance to Meithromax over time?

Official prescribing information includes warnings about the potential for bacteria to develop resistance to the drug. This occurs when bacteria change and can bypass the drug’s mechanism, which is why the medicine should only be used for bacterial infections.


Q: Is Meithromax safe to use for teenagers?

Meithromax is approved for use in the pediatric population, and dosing is determined by the child's body weight. Its safety and effectiveness for many uses are not established for children under six months of age, but it is routinely used in older children and adolescents according to official guidelines.


Q: Can men and women use Meithromax for the same conditions?

Yes, official prescribing information indicates that Meithromax is approved for use in both adult men and women for the treatment of designated susceptible bacterial infections, including respiratory, skin, and sexually transmitted diseases.


Q: Are there any special warnings for people with diabetes taking Meithromax?

While the active drug itself is not formally noted to interact with blood sugar regulation, some oral formulations, particularly the liquid suspension, contain sucrose (sugar). This factor may be a consideration for individuals managing diabetes when using the liquid form.


Q: How is Meithromax different from other drugs used for the same purpose?

A primary difference documented in regulatory literature is its unique pharmacokinetic profile. This means it is known for its ability to quickly move into body tissues and remain there for prolonged periods, which is why it often requires a shorter duration of treatment than some other types of antibiotics.


Q: Does taking Meithromax affect your ability to drive or operate machinery?

Official regulatory documents generally state that there is no evidence to suggest that Meithromax directly affects a patient's ability to drive or use heavy machinery. However, documented side effects like dizziness or somnolence (drowsiness) may occur, and patients should be aware of how they react to the medicine before performing such activities.


Q: Can Meithromax make other health conditions worse?

Official prescribing documents caution that Meithromax can exacerbate muscle weakness in persons with myasthenia gravis, a specific chronic autoimmune disease. Caution is also required for patients with pre-existing severe kidney or liver impairment or certain proarrhythmic heart conditions, as outlined in the safety sections.


Q: Does Meithromax interact with herbal remedies?

Official patient counseling information advises informing your healthcare provider about all prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are using. There is a general lack of definitive studies to confirm the safety of every single herbal remedy with the drug, and monitoring for side effects may be necessary.


Q: What is the typical timeframe for seeing the full effect of Meithromax?

Meithromax is characterized by its long half-life, meaning it remains active in the tissues for a long duration. The typical timeframe for seeing the full therapeutic effect is generally after the completion of the prescribed short course of treatment, although this can vary based on the specific infection being addressed.


Q: Does Meithromax interact with over-the-counter supplements?

Official prescribing information mandates a separation of doses from antacids containing aluminum or magnesium. For other over-the-counter supplements, patient counseling information advises notifying your doctor about all nutritional supplements being taken, as monitoring for potential side effects may be necessary.


Q: Are there common signs that Meithromax is not working?

The official warning regarding the development of drug-resistant bacteria implies a potential lack of response. Patients should monitor their condition for a lack of expected improvement or if symptoms appear to worsen, as these may be signs that the medication is not effectively controlling the bacterial pathogen.


Q: Why are the use conditions for Meithromax so specific?

The specific use conditions, such as the requirement to take certain formulations on an empty stomach and to separate the dose from specific antacids, are mandated in official documents. These rules exist to ensure the medicine is properly absorbed and reaches its required concentration in the body to work effectively.


Q: Do the side effects of Meithromax eventually go away?

Clinical trial experience documented in official labels indicates that most reported adverse reactions are mild to moderate in severity. Furthermore, these effects were generally observed to be reversible upon discontinuation of the drug.


Q: Is Meithromax addictive?

No. Meithromax (azithromycin) is classified as a prescription antibiotic. It is not listed or categorized as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or other major government regulatory bodies.


Q: Is Meithromax a Schedule V controlled substance?

No. Meithromax (azithromycin) is a prescription antibiotic and is not categorized under any schedule of controlled substances (I, II, III, IV, or V) according to major regulatory authorities.

How should Meithromax be stored and disposed of?

How to Store and Dispose of Meithromax (Azithromycin)

The official storage conditions for Meithromax are defined by its dosage form. Tablets and the unmixed powder for suspension must be stored at controlled room temperature (typically 20 C to 25 C) and protected from light in the original, tightly closed container. All forms must be kept out of the sight and reach of children.

Form Storage Rule Stability Constraint
Oral Suspension (Mixed) Do not freeze; store below 30 C. Must be discarded after 10 days.
IV Solution (Diluted) Store at room temperature or refrigerate. Stable for 7 days if refrigerated.

Unused or expired product must be disposed of in accordance with local regulations. It is officially mandated that the medicine must not be thrown into wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Meithromax found in:

A-Z Index: